Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs

Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs

The emergence of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) revolutionized the treatment of advanced-stage non-small cell lung cancer (NSCLC). Detected in more than 50% of late-stage lung adenocarcinoma in Asian patients, the EGFR mutation was regarded as a golden mutati...

Full description

Bibliographic Details
Main Authors: Dongyu Li, Jingnan Wang, Chengming Liu, Yuejun Luo, Haiyan Xu, Yan Wang, Nan Sun, Jie He
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Biomedicines
Subjects:
EGFR-TKIs
NSCLC
lung cancer
sequential therapy
resistant mechanisms
Online Access:https://www.mdpi.com/2227-9059/11/4/1141

Internet

https://www.mdpi.com/2227-9059/11/4/1141

Similar Items